1236 related articles for article (PubMed ID: 16350724)
1. [Molecular action of insulin-sensitizing agents].
Kacalska O; Krzyczkowska-Sendrakowska M; Milewicz T; Zabińska-Popiela M; Bereza T; Krzysiek-Maczka G; Krzysiek J
Endokrynol Pol; 2005; 56(3):308-13. PubMed ID: 16350724
[TBL] [Abstract][Full Text] [Related]
2. Effects of metformin on endocrine, metabolic milieus and endometrial expression of androgen receptor in patients with polycystic ovary syndrome.
Ito-Yamaguchi A; Suganuma R; Kumagami A; Hashimoto S; Yoshida-Komiya H; Fujimori K
Gynecol Endocrinol; 2015 Jan; 31(1):44-7. PubMed ID: 25237893
[TBL] [Abstract][Full Text] [Related]
3. Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome.
Costello M; Shrestha B; Eden J; Sjoblom P; Johnson N
Cochrane Database Syst Rev; 2007 Jan; (1):CD005552. PubMed ID: 17253562
[TBL] [Abstract][Full Text] [Related]
4. Effects of metformin on the expression of GLUT4 in endometrium of obese women with polycystic ovary syndrome.
Zhai J; Liu CX; Tian ZR; Jiang QH; Sun YP
Biol Reprod; 2012 Aug; 87(2):29. PubMed ID: 22572996
[TBL] [Abstract][Full Text] [Related]
5. Metformin in reproductive health, pregnancy and gynaecological cancer: established and emerging indications.
Sivalingam VN; Myers J; Nicholas S; Balen AH; Crosbie EJ
Hum Reprod Update; 2014; 20(6):853-68. PubMed ID: 25013215
[TBL] [Abstract][Full Text] [Related]
6. Adverse Long-term Metabolic and Endometrial Consequences in Women with Polycystic Ovarian Syndrome: A Report of Two Cases.
Mahmoud SA; Zhang L; Jia C; Zang H
J Reprod Med; 2016; 61(5-6):302-5. PubMed ID: 27424378
[TBL] [Abstract][Full Text] [Related]
7. Endometrium in PCOS: Implantation and predisposition to endocrine CA.
Giudice LC
Best Pract Res Clin Endocrinol Metab; 2006 Jun; 20(2):235-44. PubMed ID: 16772154
[TBL] [Abstract][Full Text] [Related]
8. Comparison of two insulin sensitizers, metformin and myo-inositol, in women with polycystic ovary syndrome (PCOS).
Fruzzetti F; Perini D; Russo M; Bucci F; Gadducci A
Gynecol Endocrinol; 2017 Jan; 33(1):39-42. PubMed ID: 27808588
[TBL] [Abstract][Full Text] [Related]
9. Metformin augments the levels of molecules that regulate the expression of the insulin-dependent glucose transporter GLUT4 in the endometria of hyperinsulinemic PCOS patients.
Carvajal R; Rosas C; Kohan K; Gabler F; Vantman D; Romero C; Vega M
Hum Reprod; 2013 Aug; 28(8):2235-44. PubMed ID: 23595973
[TBL] [Abstract][Full Text] [Related]
10. Changes in protein expression due to metformin treatment and hyperinsulinemia in a human endometrial cancer cell line.
Lange C; Machado Weber A; Schmidt R; Schroeder C; Strowitzki T; Germeyer A
PLoS One; 2021; 16(3):e0248103. PubMed ID: 33690729
[TBL] [Abstract][Full Text] [Related]
11. Insulin-sensitizing agents in polycystic ovary syndrome.
Pasquali R; Gambineri A
Eur J Endocrinol; 2006 Jun; 154(6):763-75. PubMed ID: 16728533
[TBL] [Abstract][Full Text] [Related]
12. Inflammatory cytokines and chemokines, skeletal muscle and polycystic ovary syndrome: effects of pioglitazone and metformin treatment.
Ciaraldi TP; Aroda V; Mudaliar SR; Henry RR
Metabolism; 2013 Nov; 62(11):1587-96. PubMed ID: 23958241
[TBL] [Abstract][Full Text] [Related]
13. Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review.
Palomba S; Falbo A; Zullo F; Orio F
Endocr Rev; 2009 Feb; 30(1):1-50. PubMed ID: 19056992
[TBL] [Abstract][Full Text] [Related]
14. The effects of metformin and rosiglitazone, alone and in combination, on the ovary and endometrium in polycystic ovary syndrome.
Legro RS; Zaino RJ; Demers LM; Kunselman AR; Gnatuk CL; Williams NI; Dodson WC
Am J Obstet Gynecol; 2007 Apr; 196(4):402.e1-10; discussion 402.e10-1. PubMed ID: 17403436
[TBL] [Abstract][Full Text] [Related]
15. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME - PART 2.
Goodman NF; Cobin RH; Futterweit W; Glueck JS; Legro RS; Carmina E; ; ;
Endocr Pract; 2015 Dec; 21(12):1415-26. PubMed ID: 26642102
[TBL] [Abstract][Full Text] [Related]
16. The effects of metformin on metabolic and cardiovascular risk factors in nonobese women with polycystic ovary syndrome.
Sahin Y; Unluhizarci K; Yilmazsoy A; Yikilmaz A; Aygen E; Kelestimur F
Clin Endocrinol (Oxf); 2007 Dec; 67(6):904-8. PubMed ID: 17666089
[TBL] [Abstract][Full Text] [Related]
17. The insulin-sensitizing mechanism of myo-inositol is associated with AMPK activation and GLUT-4 expression in human endometrial cells exposed to a PCOS environment.
Cabrera-Cruz H; Oróstica L; Plaza-Parrochia F; Torres-Pinto I; Romero C; Vega M
Am J Physiol Endocrinol Metab; 2020 Feb; 318(2):E237-E248. PubMed ID: 31874063
[TBL] [Abstract][Full Text] [Related]
18. Impact of metformin and rosiglitazone treatment on glucose transporter 4 mRNA expression in women with polycystic ovary syndrome.
Jensterle M; Janez A; Mlinar B; Marc J; Prezelj J; Pfeifer M
Eur J Endocrinol; 2008 Jun; 158(6):793-801. PubMed ID: 18322300
[TBL] [Abstract][Full Text] [Related]
19. Increased insulin-like growth factor-I levels in women with polycystic ovary syndrome, and beneficial effects of metformin therapy.
Berker B; Emral R; Demirel C; Corapcioglu D; Unlu C; Kose K
Gynecol Endocrinol; 2004 Sep; 19(3):125-33. PubMed ID: 15697073
[TBL] [Abstract][Full Text] [Related]
20. Preventing endometrial cancer risk in polycystic ovarian syndrome (PCOS) women: could metformin help?
Shafiee MN; Khan G; Ariffin R; Abu J; Chapman C; Deen S; Nunns D; Barrett DA; Seedhouse C; Atiomo W
Gynecol Oncol; 2014 Jan; 132(1):248-53. PubMed ID: 24183733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
